Old tumor samples may hold key to future biliary cancer treatments
NCT ID NCT07515950
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will examine stored tumor samples from 244 people diagnosed with biliary tract cancer in the last 15 years. Researchers will measure five specific markers (CLDN18.2, HER2, TROP2, PD-L1, and B7-H4) to see how common they are and how they relate to patient outcomes. The goal is to better identify which patients might benefit from targeted therapies in the future. No new treatments are given in this study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- A new test could reveal how radiation affects the liver
- Can matching cancer drugs to tumor genes prevent biliary tract cancer return?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can a dual immune booster plus chemo shrink hard-to-treat bile duct tumors?